Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inarigivir
- Development stage
- Discontinued
- Lead developer
- F-star
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Inarigivir is a small molecule investigational antiviral drug developed primarily for the treatment of chronic hepatitis B virus (HBV) infection. It acts as an agonist of retinoic acid-inducible gene I (RIG-I), a cytosolic pattern recognition receptor, thereby activating innate immune responses and triggering intracellular interferon signaling pathways to inhibit viral replication[1][6][7][8]. Inarigivir also activates NOD2, another cytosolic sensor involved in immune response, and has demonstrated broad-spectrum antiviral activity against hepatitis B and C viruses, norovirus, RSV, influenza, and parainfluenza[6]. The drug was investigated as both monotherapy and in combination with nucleos(t)ide analogues for HBV. Development was discontinued after serious adverse events occurred during phase II trials[7].
- Other names
- inarigivir
02
Targets
NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)
Beyond the preview
Go deeper on inarigivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inarigivir.